Provided by Tiger Trade Technology Pte. Ltd.

Enlivex Therapeutics Ltd.

0.3064
-0.0338-9.94%
Post-market: 0.34200.0356+11.62%19:56 EDT
Volume:3.90M
Turnover:1.39M
Market Cap:6.10M
PE:0.00
High:0.3517
Open:0.3515
Low:0.3000
Close:0.3402
52wk High:27.15
52wk Low:0.3000
Shares:19.91M
Float Shares:7.75M
Volume Ratio:6.10
T/O Rate:50.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):279.32
EPS(LYR):382.20
ROE:162.86%
ROA:-0.61%
PB:0.00
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Enlivex Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
- -
Office Location:
14 Einstein Street,Ness Ziona,Israel
Zip Code:
7403618
Fax:
- -
Introduction:
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Directors

Name
Position
Roger Pomerantz
Director and Vice Chairman of the Board
Shai Novik
Executive Chairman of the Board
Abraham Havron
Director
Gili Hart
Director
Matteo Renzi
Director

Shareholders

Name
Position
Oren Hershkovits
Chief Executive Officer
Shachar Shlosberger
Chief Financial Officer
Einat Galamidi
Chief Medical Officer
Shai Novik
Executive Chairman of the Board